{
    "nctId": "NCT01074320",
    "briefTitle": "Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors",
    "officialTitle": "Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Identify a core set of instruments for measuring musculoskeletal symptoms",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with stage I - IIIa invasive breast cancer,\n* Hormone-receptor positive cancer (either ER+ or PR+ or both),\n* Prescribed and have agreed to take exemestane, anastrazole or letrozole,\n* Have completed initial treatment of surgery, RT, and/or chemotherapy,\n* Are post-menopausal,\n* No previous history of aromatase inhibitor therapy for invasive breast cancer,\n* Have signed the consent form.\n\nExclusion Criteria:\n\n* History of rheumatoid arthritis,\n* Unable to read or understand English,\n* History of psychiatric disability affecting informed consent or compliance with study procedures.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}